Cow's Milk Protein Allergy (CMPA) - A Detailed Overview

1. Epidemiology

• Affects approximately 2-3% of infants globally; some estimates run higher.
• More common in formula-fed than breastfed infants.
• Resolves in the majority of cases during childhood (most children tolerate milk by age 5-6 years).
• Uncommon in adults.
• Rising reported prevalence of food allergies globally.

2. The Culprit Proteins

3. Immunological Classification

3a. IgE-Mediated (Immediate-Type) CMPA

• Accounts for approximately 50% of cases.
• Reaction onset: within minutes to 2 hours of exposure.
• Involves sensitization of mast cells via IgE antibodies.

• Sensitization Phase: Antigen-presenting cells present milk proteins to naive CD4+ T cells → Th2 polarization → B-cell class switching → IgE production → IgE binds to mast cell Fc receptors.
• Activation Phase: Re-exposure to milk proteins cross-links mast cell-bound IgE → degranulation.
• Effector Phase: Release of histamine, prostaglandins, leukotrienes → smooth muscle contraction, mucous secretion, eosinophil recruitment, vascular permeability.

• Predominance of Th2 lymphocytes with elevated IL-4 and IL-5
• Enhanced mast-cell degranulation
• Increased antigen resorption due to loss of mucosal integrity
• Genetic predisposition (atopic background)

3b. Non-IgE-Mediated (Delayed-Type) CMPA

• T-cell and eosinophil-mediated.
• Reaction onset: hours to days after exposure.
• Skin-prick tests and serum-specific IgE are typically negative.
• Harder to diagnose.

3c. Mixed (IgE + Non-IgE) CMPA

• Seen in eosinophilic esophagitis (EoE), eosinophilic gastroenteritis, and allergic eosinophilic proctocolitis.

4. Sensitization Pathways

• Skin barrier disruption (especially eczema/atopic dermatitis) - now recognized as a major primary sensitization route.
• Gut exposure to undegraded protein antigens circulating in the bloodstream.
• The intestinal microbiome plays a role: disease-associated dysbiosis can promote food allergy susceptibility.

5. Clinical Manifestations

Cutaneous (most common, ~50-70%)

• Urticaria and angioedema (IgE-mediated, immediate)
• Worsening of atopic dermatitis/eczema (often delayed, mixed)
• Flushing

Gastrointestinal (~50-60%)

• Reflux, regurgitation, vomiting
• Abdominal cramping, colic, bloating
• Diarrhea (with or without blood)
• Constipation
• Hematemesis, melena (blood in stool)
• Malabsorption, failure to thrive
• Allergic gastritis (mucosal hemorrhage, neutrophilic and eosinophilic infiltrate on biopsy)

Respiratory (~20-30%)

• Rhinitis, nasal congestion
• Wheezing, asthma exacerbation
• Cough
• Rarely: Heiner syndrome (food-induced pulmonary hemosiderosis) - diffuse pulmonary hemorrhage associated with cow's milk protein allergy in infants

Systemic

• Anaphylaxis (severe, life-threatening; IgE-mediated; risk is real with true IgE-mediated CMPA)

6. Specific Non-IgE-Mediated Syndromes (Cow's Milk as a Key Trigger)

7. Diagnosis

History

• Timing and pattern of symptoms after milk intake
• Family history of atopy
• Response to milk elimination

Allergy Testing (for IgE-mediated CMPA)

Important: Elevated IgG to milk proteins does NOT indicate allergy - it reflects only food exposure. Do not use IgG testing for diagnosis.

Fecal calprotectin is elevated in CMPA but not recommended as a routine diagnostic tool due to limited data.

Elimination and Challenge

• Elimination diet: Remove all cow's milk protein from diet (and from maternal diet if breastfeeding) for 2-4 weeks.
• Symptom resolution with elimination supports CMPA.
• Oral Food Challenge (OFC) / Double-Blind Placebo-Controlled Food Challenge (DBPCFC) - considered the diagnostic gold standard. Carries anaphylaxis risk in IgE-mediated cases; must be done in a supervised setting.

Endoscopy (when needed)

• Can rule out eosinophilic esophagitis, Crohn's disease.
• Allergic gastritis on biopsy shows eosinophilic and neutrophilic infiltrate with mucosal hemorrhage.

8. Management

Step 1: Avoidance

• Complete elimination of cow's milk protein from the diet is the foundation of management.
• In breastfed infants: mother eliminates all dairy from her own diet.
• In formula-fed infants: switch to appropriate alternative formula.

Alternative Formulas

Pharmacologic Treatment

• Oral cromolyn: may help some patients.
• Antihistamines: symptomatic relief for mild IgE-mediated reactions.
• Epinephrine (adrenaline) auto-injector: prescribed for patients at risk of anaphylaxis; must be immediately available.

Oral Immunotherapy (OIT) - Emerging

• OIT significantly facilitates desensitization in children with CMA (RR 2.51, 95% CI: 1.54-4.09).
• Tolerance threshold at oral food challenge increased significantly (SMD 3.58).
• Cow milk sIgE and casein sIgE titers decreased after OIT.
• Risk of adverse reactions was not higher than controls.
• Caution: late complication of eosinophilic esophagitis has been reported; long-term efficacy needs more study. [PMID: 40534871]

9. Prognosis and Natural History

• Approximately 50% of children tolerate milk by age 1 year.
• ~80-85% outgrow it by age 3-5 years.
• IgE-mediated CMPA tends to persist longer than non-IgE-mediated.
• High casein sIgE titers and component sensitization predict persistence.
• Coexisting multiple food allergies or severe eczema predicts slower resolution.
• Rarely persists into adulthood.

10. Key Differential Diagnoses

Summary